Dutkiewicz S
Department of Urology, Central Clinical Hospital, Warsaw, Poland.
Mater Med Pol. 1996 Jul-Sep;28(3):93-102.
To evaluate the efficacy and tolerability of doxazosin in the long-term (3yr.) treatment of bladder outflow obstruction resulting from BPH. Data were obtained in 64 patients with BPH. The main outcome measures were urodynamic and symptomatic evaluation for efficacy. In the three year follow up study on doxazosin, including 33 patients remaining on the drug drug and 11 operated (total 44) and excluding those who abandoned the therapy or died, the positive effect of the treatment was found in 75 percent and failure in 25 percent of cases. Doxazosin was well-tolerated and produced both urodynamic and symptomatic improvement in men with BPH. Results from clinical trials demonstrate doxazosin is effective and safe and well tolerated in both normotensive and hypertensive patients with BPH.
评估多沙唑嗪长期（3年）治疗良性前列腺增生所致膀胱流出道梗阻的疗效和耐受性。收集了64例良性前列腺增生患者的数据。主要疗效指标为尿动力学和症状评估。在对多沙唑嗪的三年随访研究中，包括33例继续用药的患者和11例接受手术的患者（共44例），排除那些放弃治疗或死亡的患者，75%的病例治疗有积极效果，25%的病例治疗失败。多沙唑嗪耐受性良好，对良性前列腺增生男性患者的尿动力学和症状均有改善。临床试验结果表明，多沙唑嗪在血压正常和高血压的良性前列腺增生患者中均有效、安全且耐受性良好。
